Diabetes can cause diabetic neuropathy (DN), a frequent and crippling consequence that is characterised by nerve damage that impairs sensation, causes persistent pain, and impairs motor function. In order to reduce discomfort, delay the development of the illness, and enhance overall quality of life, pharmaceutical treatments are an essential part of managing the symptoms of DN. Antidepressants like amitriptyline and duloxetine, as well as anticonvulsants like pregabalin and gabapentin, are the mainstays of first-line treatments for neuropathic pain (DN). Opioids and tramadol are used in more severe or unresponsive situations; however, their usage is restricted due to adverse effect and dependency concerns. Topical medications, such as lidocaine and capsaicin, are additional therapy for localised pain management. Emerging pharmaceutical approaches aim to treat the underlying pathophysiology of DN in addition to relieving symptoms. More efficient and focused treatments are still needed, despite recent developments. It is probable that in the future, pharmacological strategies will progress towards customised therapy regimens that incorporate established and novel treatments to effectively tackle the intricacies of diabetic neuropathy.